Effect of zinc and copper on the interaction of daunorubicin with cardiac myosin

Synthesis and preliminary therapeutic evaluation of copper nanoparticles against diabetes mellitus and -induced micro- (renal) and macro-vascular (vascular endothelial and cardiovascular) abnormalities in rats

Current study synthesized and investigated the effect of low-dose copper nanoparticles (CuNPs) against diabetes mellitus and -induced experimental micro- (nephropathy) and macro-vascular (cardio and endothelium) complications.

Administration of chromium(III) and manganese(II) as a potential protective approach against daunorubicin-induced cardiotoxicity: in vitro and in vivo experimental evidence

Daunorubicin (DNR) is a widely used antitumor drug, but its application is limited because of its cardiotoxic side effects. The present study was designed to investigate the interaction between DNR and cardiac myosin (CM) in the presence of chromium(III) (Cr(3+)) and manganese(II) (Mn(2+)) using fluorescence spectrometry under simulative physiological conditions with the aim of exploring the influence of metal ion on DNR-CM complex and finding out an aggressive approach to abrogate of DNR-induced cardiotoxicity. In detail, the quenching and binding constant of ternary system, including metal ion, DNR, and CM, were measured and compared with the DNR-CM. The data from in vitro experiments indicate that the presence of Cr(3+) or Mn(2+) distinctly decreased the binding force between DNR and CM, and alleviated the cardiac toxicity caused by DNR. In addition, the variations in mice body weight and myocardial enzyme level were examined by in vivo experiments. Animals receiving Cr(3+) or Mn(2+) supplementation of DNR showed preservation of the normal pattern of the heart, especially 2.0 mg Cr(3+)/kg body wt or 50.0 mg Mn(2+)/kg body wt exhibited an obviously protective effect accompanied with body weight raise when compared with the mice treated with DNR alone, decreased the ratio of heart to body weight (BW) and the ratio of left ventricular mass to BW to the normal levels, and inhibited the leak of myocardial enzyme caused by DNR. As a result, this study suggests that pretreatment of lower dose of Cr(3+) (2 mg/kg wt) and moderate dose of Mn(2+) (50 mg/kg wt) might be useful and play an important role in ameliorating the cardiotoxicity of DNR treatment in cancer patients.

Effect of selenium on the interaction between daunorubicin and cardiac myosin

The interactions between selenium (sodium selenite), anthracycline antibiotics daunorubicin (DNR), and major contractile protein cardiac myosin (CM) were investigated. The results showed that the binding force between selenium and CM was 100 times stronger than that of DNR and CM. There was no marked influence on fluorescence intensity of DNR-CM at selenium concentrations of up to 20 μM. The co-administration of selenium (0.5-10.0 μg Se/ml) together with DNR resulted in a significant reduction in mice cardiotoxicity. However, selenium at the dose of 50.0 or 100.0 μg Se/ml afforded no obvious protection. The data indicate that selenium in the form of sodium selenite at appropriate dosage (<10.0 μg Se/ml) diminish the cardiac toxicity of DNR, potentially allowing the use of DNR at higher dosages in clinical cancer chemotherapy.